DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma; Ocular Hypertension

Intervention: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Drug); latanoprost 0.005% (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


A three-month evaluation comparing the safety and efficacy of a fixed combination of 0. 2% brimonidine tartrate/0. 5% timolol maleate with that of latanoprost 0. 005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Primary outcome: Intraocular Pressure (IOP) at Week 12


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: 1. Be at least 18 years of age; 2. Give written informed consent; 3. Be in good general health as determined by your doctor; 4. Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension; 5. If you are a female of child bearing potential, you must be willing to practice effective contraception for the duration of the study (i. e., abstinence, spermicide, condoms, or birth control pills); 6. Understand the study instructions, and be able to follow the study instructions; and 7. Be likely to complete the entire study period (12 weeks), including all regularly scheduled study visits. Exclusion Criteria: 1. Have any active ocular disease other than glaucoma or ocular hypertension that would interfere with study interpretation; 2. Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; and 3. Concurrent participation or prior participation in any investigational drug or device study within the last 30 days prior to the Screening Visit

Locations and Contacts

Slingerlands, New York, United States
Additional Information

Starting date: December 2008
Last updated: August 17, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017